17th Dec 2015 15:13
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | ||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | ALLIANCE PHARMA PLC | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | √ | |||
Other (please specify): | Placing shares and exercise of broker's option | √ | ||
3. Full name of person(s) subject to thenotification obligation: | NIGEL WRAY | |||
4. Full name of shareholder(s) (if different from 3.): | PERSHING NOMINEES LIMITED ROY NOMINEES LIMITED | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 17 December 2015 | |||
6. Date on which issuer notified: | 17 December 2015 | |||
7. Threshold(s) that is/are crossed orreached: | 7% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
Ordinary shares GB0031030819 | 37,376,510 | 37,376,510 | 15,511,922 | 15,511,922 | 21,864,588 | 3.31% | 4.67% | |||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
| Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
37,376,510
| 7.98% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees Pershing Nominees Limited 15,511,922 The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited - 21,864,588 | ||
Proxy Voting: | ||
10. Name of the proxy holder: | N/A | |
11. Number of voting rights proxy holder will cease to hold: | N/A | |
12. Date on which proxy holder will cease to hold voting rights: | N/A | |
13. Additional information: | Figures are based on a total number of voting rights of 468,179,146
| |
14. Contact name: | Nigel Wray | |
15. Contact telephone number: | 020 7647 7647 | |
Related Shares:
Alliance Pharma